| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
35 |
| Employees |
100 |
| Revenues (TTM) (Millions $) |
50 |
| Net Income (TTM) (Millions $) |
17 |
| Cash Flow (TTM) (Millions $) |
136 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Principia Biopharma Inc is a clinical-stage biopharmaceutical company that focuses on discovering and developing small molecule inhibitors of oncology and autoimmune targets. The company has developed a unique drug discovery platform known as Tailored Covalency, which allows them to selectively target specific enzymes and pathways associated with diseases.
In particular, Principia Biopharma is focused on developing therapies for patients with multiple sclerosis (MS), lupus, and cancers such as mantle cell lymphoma (MCL) and solid tumors. The company's lead drug candidate, PRN1008, is a reversible covalent inhibitor of Bruton's tyrosine kinase (BTK), which has shown promising efficacy in Phase 2 clinical trials for the treatment of pemphigus, a rare autoimmune skin disease, and ITP, a blood clotting disorder.
Principia Biopharma's drug discovery platform utilizes structure-based drug design, which enables them to create small molecules with high potency and selectivity for their intended targets, while minimizing off-target effects. The company also employs computational chemistry, protein engineering, and medicinal chemistry to design and optimize drug candidates.
The company was founded in 2009 by a group of industry veterans with extensive experience in developing small molecule drugs. It is based in South San Francisco, California, with additional locations in Cambridge, Massachusetts, and Durham, North Carolina. Principia Biopharma has partnerships with several major pharmaceutical companies, including Sanofi and AbbVie, which are helping to advance its drug discovery programs.
Overall, Principia Biopharma is a cutting-edge biopharmaceutical company that has made significant strides in developing novel therapies for patients with serious diseases. Its unique drug discovery platform and strong partnerships with industry leaders make it well-positioned to continue making a major impact in the world of biotechnology.
Company Address: 220 East Grand Avenue South San Francisco 94080 CA
Company Phone Number: 416-7700 Stock Exchange / Ticker: NASDAQ PRNB
|
%